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Abstract
Human immunodeficiency virus (HIV-1) is, like most pathogens, under selective pressure to escape the immune system of its
host. In particular, HIV-1 can avoid recognition by cytotoxic T lymphocytes (CTLs) by altering the binding affinity of viral
peptides to human leukocyte antigen (HLA) molecules, the role of which is to present those peptides to the immune
system. It is generally assumed that HLA escape mutations carry a replicative fitness cost, but these costs have not been
quantified. In this study, we assess the replicative cost of mutations which are likely to escape presentation by HLA
molecules in the region of HIV-1 protease and reverse transcriptase. Specifically, we combine computational approaches for
prediction of in vitro replicative fitness and peptide binding affinity to HLA molecules. We find that mutations which impair
binding to HLA-A molecules tend to have lower in vitro replicative fitness than mutations which do not impair binding to
HLA-A molecules, suggesting that HLA-A escape mutations carry higher fitness costs than non-escape mutations. We argue
that the association between fitness and HLA-A binding impairment is probably due to an intrinsic cost of escape from HLA-
A molecules, and these costs are particularly strong for HLA-A alleles associated with efficient virus control. Counter-
intuitively, we do not observe a significant effect in the case of HLA-B, but, as discussed, this does not argue against the
relevance of HLA-B in virus control. Overall, this article points to the intriguing possibility that HLA-A molecules
preferentially target more conserved regions of HIV-1, emphasizing the importance of HLA-A genes in the evolution of HIV-1
and RNA viruses in general.
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Introduction
The evolutionary dynamics of viral infections are often
characterized by the opposing forces of immune control and viral
escape. These forces shape both the within-host dynamics of
infections as well as the dynamics of spread on an epidemiological
level. At the within-host level, the role of the opposing forces are
manifest in chronic infections such as HIV, SIV, and HCV, where
it has been shown that the virus population frequently escapes
immune control by B- or T-cell responses [1–8]. Moreover, in
HIV/SIV, slow disease progression is associated with efficient
immune control via protective human leukocyte antigen (HLA)
genes; see [9–11], and escape events can precipitate the loss of
immune control [3,12,13]. At the epidemiological level, the
selection for escape imposed by the host population can be traced
in the genetic structure of viral infections [14–17].
The balance between immune control and escape often affects the
success of vaccines.Vaccinesagainstviral infections characterized by
complete absence of escape, such as smallpox, measles, mumps and
rubella, are typically highly protective [18], whereas vaccines against
viruses which periodically escape immune control, such as influenza,
require periodic updating [19–21]. In HIV-1, antigenic diversity,
often stemming from escape at the within-host level, represents a
formidable obstacle for any potential vaccine to overcome [22–24].
Deeper insight into the coevolutionary dynamics of immune
control and viral escape requires an improved quantitative
understanding of the benefits and costs of escape from the
immune responses. The literature on HIV-1 and SIV escape
clearly documents the existence of costs and benefits for viral
escape as well as the necessity of quantifying them. A good
example is the escape from the presentation by major histocom-
patibility complex (MHC) class I molecules, in humans encoded by
HLA genes [3]. Furthermore, escape mutations often revert in
HLA-mismatched patients [25–27] and they are often followed by
compensatory mutations [28–30], suggesting that escape muta-
tions are costly. Large variability in the cost of escape mutations
PLoS Computational Biology | www.ploscompbiol.org 1 May 2012 | Volume 8 | Issue 5 | e1002525has been demonstrated experimentally [31], and mathematical
models have shown that the dynamics of immune escape strongly
depend on the cost of escape mutations both at the within-host and
the epidemiological level [32–34]. Taken together these studies
underline the importance of assessing the replicative cost of escape
mutations.
In this study, we quantified the fitness cost of those mutations in
HIV-1 protease (PR) and reverse transcriptase (RT) which are
likely to escape the presentation of HLA molecules using an in silico
approach, focusing on escape from presentation by HLA-A and
HLA-B molecules. To this end, we analyzed a dataset of more
than 70’000 genetic sequences of HIV-1 PR and RT from the
North American population. Specifically, we combined two
computational approaches: First, we used the results of a ridge-
regression approach to quantify the impact of single amino acid
substitutions in the region of interest on viral replicative capacity in
vitro [35]. Second, the impact of these mutations on binding
affinity to various HLA molecules was predicted using a neural
network approach, as implemented in [36,37]. Combining these
two methods we examined whether mutations which are more
likely to disrupt binding to HLA molecules carry a higher
replicative cost in vitro than other mutations.
Materials and Methods
Data
Over 70’000 virus sequences from HIV-1 subtype B were
assayed for the replicative capacity of the Pol gene, specifically
the entire protease (PR) and positions 1 to 305 of the reverse
transcriptase (RT). The assay is described in detail in ref. [38].
In brief, the region of interest (404 amino acids) was inserted
into a viral backbone derived from the NL4-3 molecular clone.
The NL4-3 clone was modified so that it can go through a single
round of replication. Replicative capacity for each genetic
variant was then assessed in vitro by measuring the total
infectious progeny virus produced after a single round of
replication.
Quantification of fitness costs
The quantification of fitness costs was based on a method
described in detail elsewhere [35]. In short, the data described
above were fitted to a fitness model of single and double mutations
to estimate the effect of these mutations on the viral replicative
capacity in vitro using a machine-learning approach (generalized
kernel ridge regression). This fitness prediction model had
previously been trained on a data set of 65,000 sequences and
had been cross-validated on 5,000 sequences, where it explained
between 35% and 66% of the variance in fitness depending on the
environment in which replication was measured. Specifically, the
model used here is based on the estimated main effects and
pairwise epistatic effects of the 1’848 amino acid variants found in
these sequences, and therefore can predict the fitness of all 1’848
single non-synonymous mutations which naturally occurred in the
viral population derived from North American patients.
Here we used this predictive model to calculate the fitness effects
of single mutants, which were generated by substituting a single
amino acid in the wild-type NL4-3 sequence. The relative fitness
of such a single mutant was then given by its predicted replicative
capacity relative to the predicted replicative capacity of the NL4-3
sequence. The predicted fitness of the NL4-3 sequence was
therefore equal to 1.
Epitope prediction
In order to achieve broad HLA coverage, we used the pan-
specific method NetMHCpan2.4 [36,37] to predict binding
affinities of peptides to HLA class I molecules. This machine-
learning method (neural network approach) had been trained on a
large set of quantitative MHC-peptide binding data for more than
80 human and non-human MHC class I molecules (w90%
human). The method extrapolated the ‘‘rules’’ of MHC-peptide
binding from the training set to predict the binding affinity of
MHC:peptide combinations that were not part of the training
process. In this study we focused on two of three HLA class I loci:
HLA-A and HLA-B. In a benchmark study based on these two
genes, NetMHCpan was shown to outperform other pan-specific
prediction methods [39]. Binding predictions to HLA-C were
ignored because of performance issues.
To utilize NetMHCpan to predict epitopes in PR (amino acids
1–99) and RT (amino acids 1–305), we cleaved the corresponding
amino acid sequence of NL4-3 into all possible peptides of length 9
(9mers). We quantified the binding affinity for each peptide:HLA
combination by predicting a binding affinity of the complex, which
was characterized by an IC50 value (concentration at which half-
maximal inhibition in the assay was achieved). A low IC50 score
translated into a high binding affinity, and a high IC50 score
translated into a low binding affinity. A peptide was then
considered an epitope if its predicted binding affinity for a given
HLA molecule exceeded either a relative or an absolute threshold.
According to the absolute criterion, a peptide was an epitope for a
given HLA allele if the obtained IC50 score was lower than
500 nM, as suggested experimentally [40]. According to the
relative criterion, a peptide was an epitope for a given HLA allele
if the obtained IC50 score fell within the bottom 1% of all scores
obtained for this HLA allele based on a large set (n~105)o f
random natural peptides. Both binding definitions are widely used
in the literature [41–43].
Impairment of binding affinity in mutated epitopes
The degree to which a single mutation in a peptide impairs its
binding to an HLA allele is considered here only if the peptide was
an epitope for the given allele based either on the relative or the
absolute criterion. Hence, assessing binding impairment depends
Author Summary
Our immune system can recognize and kill virus-infected
cells by distinguishing between self and virus-derived
protein fragments, called peptides, displayed on the
surface of each cell. One requirement for a successful
recognition is that those peptides bind to the human
leukocyte antigen (HLA) class I molecules, which present
them to the immune system. As a counter-strategy, human
immunodeficiency virus type 1 (HIV-1) can acquire
mutations that prevent this binding, thereby helping the
virus to escape the surveillance of T-lymphocytes. It is
likely that the virus pays a replicative cost for such escape
mutations, but the magnitude of this cost has remained
elusive. Here, we quantified this fitness cost in HIV-1
protease and reverse transcriptase by combining two
computational systems biology approaches: one for
prediction of in vitro replicative fitness, and one for the
prediction of the efficiency of peptide binding to HLA. We
found that in viral proteins targeted by HLA-A molecules,
mutations which disrupt binding to those molecules carry
a lower replicative fitness than mutations which do not
have such an effect. We argue that these results are
consistent with the hypothesis that our immune systems
might have evolved to target genetic regions of RNA
viruses which are costly for the pathogen to alter.
Fitness Cost of Escape from HLA in HIV-1
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binding affinity due to single mutation in epitopes was defined as
DB~
log500
log50k
logBm{logBwt
logBHLA
, ð1Þ
where BHLA is the IC50 binding threshold to a HLA molecule in
question, Bm is the IC50 score of the mutated peptide to this HLA
molecule, Bwt is the IC50 score of the wild-type (non-mutated)
peptide to this HLA molecule, and 50k denotes the value of
50,000 nM considered a maximal experimental sensitivity thresh-
old. If multiple HLA molecules were affected by a single mutation,
the strongest impairment was taken into account. Note that for the
absolute criterion used here, the multiplication factor in the front
reduces to 1, as BHLA~500nM for each HLA molecule.
Frequency of HLA-alleles and escape
The frequency of a given HLA allele in the US population was
estimated from a HLA haplotype study in the US population
stratified by ethnicity [44]. The HLA alleles used for this study
consisted of all alleles for which we obtained frequency data and
which featured in netMHCpan2.4, giving overall 98 HLA-A
alleles and 184 HLA-B alleles. An expected frequency of each
given HLA allele was calculated as the mean ethnicity-stratified
frequency, weighted by the HIV-1 prevalence estimates in the US
population for different ethnicities [45]. The list of all HLA alleles
used in this study, together with the calculated frequency values
are given in Table S1.
To investigate the role of the selective pressure at the population
level, we defined a ‘mutation impact’ and a ‘population-weighted
mutation impact’, given by
Xi
I~
X n(i)
j
DBij, Xi
PI~
X n(i)
j
DBijfj, ð2Þ
where DBij is an impairment of binding HLA molecule j due to
mutation i, fj is the expected frequency of HLA j in the
population, and n(i) is the number of HLA molecules binding to
the wild-type; all values characterized by DBijv0 were ignored.
We classified HLA alleles that occur at frequencies of 0.5% or
lower in the host population as infrequent, assuming that these
HLA alleles impose negligible selection pressure for escape in the
host population. In the analysis of population-independent effects
we removed all frequent HLA alleles from the analysis.
Protective and non-protective alleles
To identify protective and non-protective HLA alleles, we
assigned a relative hazard for progression to AIDS (RH) to each
HLA molecule, based on a survival analysis of HIV-1 positive
patients from an earlier study [46]. HLA alleles with a low RH
value tend to be associated with long-term non-progression to
AIDS, while HLA alleles with a high RH value tend to be
associated with rapid progression to AIDS. As the relative hazard
values in this study had been associated with low resolution HLA
molecules (two-digit, e.g., HLA-A*02) rather than with high-
resolution HLA molecules (four-digit, e.g., HLA-A*02:01), in the
analysis we assigned the relative hazard values to all HLA alleles of
a particular group. For example, the RH~0:57, associated with
the allele HLA-A*26, was assigned to HLA-A*26:01, -A*26:02,
-A*26:03, -A*26:07, -A*26:08, -A*26:09, and -A*26:12. In our
analysis, protective HLA alleles were defined as the 10 alleles
(according to the two-digit classification) with the lowest RH value
(HLA-B*58, -B*27, -B*57, -A*26, -B*51, -A*11, -A*32, -B*13,
-B*14, -A*31), and non-protective HLA alleles were defined as the
10 alleles (according to the two-digit classification) with the highest
RH value (HLA-A*66, -A*74, -B*35, -B*53, -B*45, -B*50, -A*33,
-B*39, -A*68, -B*56). According to the four-digit classification this
corresponds to 54 protective HLA alleles and 60 non-protective
alleles.
Statistical analysis
The non-parametric Mann-Whitney or Wilcoxon signed-rank
test was used for statistical comparisons of data samples with
measured replicative fitness. The non-parametric Spearman rank
test was used to calculate correlation coefficients between fitness
and impairment of binding, with the confidence intervals
calculated using the Fisher transformation. Results with pƒ0:05
or less were considered significant; results with 0:05vpƒ0:1 were
considered as showing a trend of significance. All correlations and
data analyses were performed using the R software package [47].
Results
In order to test whether the fitness cost of single mutations is
associated with their impact on HLA presentation, we analyzed
the correlation between the predicted relative fitness of single
mutations and their effect on HLA binding affinity. The in vitro
fitness of mutations (replicative capacity) was predicted via ridge
regression [35] and their impact on HLA presentation was
predicted via a neural-networks approach [37]; see Materials &
Methods. We first assessed the relation between the fitness of
mutations and their effect on HLA binding. To that end, we
quantified the impairment of binding caused by each mutation as
a log of the ratio of binding affinity prior to the mutation and after
the mutation, as given by equation (1). The analysis was performed
once for HLA-A molecules, and once for HLA-B molecules.
Specifically, in the analysis for HLA-A we considered all mutations
in epitopes restricted by HLA-A molecules, and in the analysis for
HLA-B we considered all mutations in epitopes restricted by HLA-
B molecules (even though these sets of mutations may overlap). If,
for a given HLA locus (A or B), a mutation was part of more than
one epitope, the strongest effect was considered for that HLA
locus, ensuring that one mutation gave rise to a single data point
per HLA locus. Fig. 1 shows a correlation between the predicted
fitness of single mutations and their impact on binding affinity to
HLA-A and HLA-B molecules. The disruptive effect of mutations
on binding between HIV-1 peptides and HLA-A molecules was
found to correlate significantly with the fitness of those mutations,
independent of the epitope definition employed (absolute criterion
assumes same binding threshold for each HLA molecule; relative
criterion assumes that each HLA molecule binds a similar number
of peptides; see Materials & Methods), however no such
correlation was observed for HLA-B molecules (HLA-A: absolute
criterion: r~{0:131, pv5|10{6; relative criterion:
r~{0:154, pv10{5; HLA-B: absolute criterion: pw0:1; relative
criterion: pw0:5). Thus, mutations which disrupt binding to HLA-
A molecules seem to carry a higher fitness cost than mutations that
do not.
To assess whether this association holds independently of the
binding criterion employed, we examined the association between
fitness and change in binding for a published list of experimentally
defined optimal CTL epitopes and the corresponding HLA
molecules [48], which defined the used peptide:HLA complexes.
We observed a trend of a negative correlation between fitness and
binding impairment when mutations in peptides restricted by both
HLA-A and HLA-B were considered (r~{0:07, p~0:055,
Fitness Cost of Escape from HLA in HIV-1
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tions in HLA-A (pw0:1, n~310) or HLA-B (pw0:1, n~577).
Although the first result seems to support the notion of a negative
correlation between replicative fitness and binding impairment to
HLA molecules in the HIV-1 region examined, it remains not fully
clear whether the lack of a strong signal is due to a low number of
HLA:peptide pairs provided in the list of best-defined CTL
epitopes (81 instead of 1850 and 796 predicted ones for the
absolute and relative criterion, respectively), or due to any
problems associated with the classification of optimal epitopes.
The association between the effect of a mutation on fitness and
its predicted effect on HLA-A binding could be due to two,
mutually not exclusive, factors. First, there might be a population
effect caused by selection for escape at the host population level, as
shown in Fig. 2. Since our data are not based on random
mutations but mutations as they are observed in viral populations
sampled from the infected host population, we would expect
mutations with a high replicative cost (i.e., low replicative capacity
in vitro) to be underrepresented in our dataset. However, for escape
mutations such replicative cost could be offset by the benefit of
conferring escape, especially if the mutant confers escape in a large
fraction of the host population. For this reason, two mutations of
the same replicative capacity, one escaping a large fraction of the
host population and another escaping none, would not spread
evenly in the host population because the escape mutation would
have a higher in vivo fitness than the non-escape mutation, and
consequently the escape mutation would be present at a higher
frequency in the population than the non-escape mutation. The
resulting excess of escape mutations with high replicative cost
would manifest itself in the data as a difference in relative fitness in
vitro between the two types of mutations (see also Fig. 2). We expect
this effect to be the most dramatic for mutations with high
replicative cost because mutations with a low replicative cost will
most likely occur in the dataset even if they carry no additional
advantage against the immune response. Second, there could be
an intrinsic effect stemming from intrinsic differences between
mutations that reduce HLA-A binding and mutations that do not.
To test the first hypothesis, we examined whether the observed
dependence of the binding effect of single mutations on their
fitness becomes more prominent if the frequency of HLA-A alleles
are taken into account. To this end we defined a ‘mutation
impact’, XI, which calculates the unweighted binding impairment
to all HLA molecules which bind to the wild-type, and a
‘population-weighted mutation impact’, XPI, which calculates
the same effect but weighted by the frequencies of particular HLA
alleles (see Materials & Methods). A significant correlation
between XI and fitness was observed (absolute criterion:
r~{0:098, pv0:005; relative criterion: r~{0:094, pv0:05),
as well as between XPI and fitness (absolute criterion:
r~{0:0864, pv0:005; relative criterion: r~{0:100,
Figure 1. Cost of mutations which impair the HLA-binding. (Top row) Effect of mutations on binding affinity to HLA-A molecules according
to two alternative epitope definitions (absolute criterion: n~1229, relative criterion: n~854). In both cases we observed a significant correlation
between the fitness of single mutants and the impairment of binding to HLA-A (absolute criterion: r~{0:131, pv5|10{6; relative criterion:
r~{0:154, pv10{5). Each datapoint corresponds to a single amino acid substitution in the genetic region restricted by HLA alleles of the
corresponding locus, A or B. Note, that if multiple HLA molecules were affected by a single mutation at a given locus, the strongest impairment was
plotted here. (Bottom row) Effect of mutations on binding affinity to HLA-B molecules for the two alternative epitope definitions (absolute criterion:
n~1431, relative criterion: n~962). Here, no significant correlation between the quantities in question was found (absolute criterion: pw0:1; relative
criterion: pw0:5). For the sake of illustration, the blue line shows the best fit of a linear regression and the 95% confidence interval.
doi:10.1371/journal.pcbi.1002525.g001
Fitness Cost of Escape from HLA in HIV-1
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significantly different (absolute criterion: CII~({0:157;{0:039),
CIPI~({0:145;{0:027); relative criterion: CII~({0:168;
{0:019), CIPI~({0:175;{0:025)). Furthermore, a partial corre-
lation between fitness and XPI corrected for XI,w a sf o u n dt ob en o n -
significant (absolute criterion: pw0:5; relative criterion: pw0:1).
Hence, our analysis shows that the lower replicative fitness of
mutationswhichimpairbindingtoHLA-Amoleculesisunlikelytobe
caused by the population effect explained above.
To test the second hypothesis (intrinsic effect), we considered
only escape mutations from rare HLA-A alleles (less frequent than
0.5%) because such rare alleles are likely to impose a negligible
selective pressure on the virus population. Fig. 3 shows a
correlation between fitness and impairment of binding due to
single mutations in regions targeted by such infrequent HLA-A
alleles, in analogy to Fig. 1. For both definitions of escape, we saw
a significant correlation between fitness and impairment of binding
affinity (absolute criterion: r~{0:117, pv5|10{5; relative
criterion: r~{0:128, pv5|10{4). Our analysis thus suggests
that the association between replicative cost and escape from
HLA-A-binding in HIV-1 may be due to intrinsic differences
between the mutational effects of escape versus non-escape
mutations.
Finally, we examined whether escape mutations from the
presentation by protective HLA alleles are more costly than escape
mutations from the presentation by non-protective HLA alleles.
We defined protective and non-protective HLA alleles based on
the associated relative hazard of progression to AIDS reported in
an earlier study [46] (see also Materials & Methods). Fig. 4 shows a
correlation between fitness and binding, in analogy to Fig. 1, for
the 10 most protective and the 10 most non-protective HLA allele
groups. A significant correlation is observed in the case of
protective HLA alleles (absolute criterion: r~{0:115, pv10{4;
relative criterion: r~{0:0733, pv0:05) but not in the case of
non-protective HLA alleles (absolute criterion: pw0:1; relative
criterion: pw0:5). Furthermore, we observed that the correlations
for protective HLA alleles became stronger when performed on
the subset of protective HLA-A alleles (absolute criterion:
r~{0:24, pv5|10{12; relative criterion: r~{0:31,
pv5|10{8), and non-significant when performed on the subset
of protective HLA-B alleles (both criteria: rw0, pw0:1). An
analysis based on a dataset from a different study by Gao et al.
[49] revealed qualitatively identical results. Our results thus
suggest that escape from protective HLA alleles (particularly HLA-
A alleles) may be more costly than escape from non-protective
HLA alleles.
Discussion
This study provides, to our knowledge, the first quantitative
assessment of the fitness cost of escape mutations which disrupt
presentation by HLA-A and HLA-B molecules. Our results
indicate that the fitness cost of mutations increases with the
resulting impairment of binding strength to HLA-A, suggesting
that a higher tendency to escape HLA binding is more costly in
terms of replicative fitness.
Our analysis suggests that the increased replicative cost of those
mutations which tend to impair binding to HLA-A molecules is
due to an intrinsic property of the virus, where HLA molecules
preferentially bind peptides in which escape mutations are
Figure 2. Population effect in the observed cost of escape from HLA presentation. The distribution of replicative fitness effects (DFE) of
random mutations in HIV-1 (green) will differ from the corresponding distribution of mutations derived from the patient population (blue/orange) as
the latter will feature only mutations which have undergone selection. Mutations with a particularly high replicative cost (i.e., low replicative capacity)
will have a low probability of being present in the patient-derived data because they will persist at very low frequencies in the virus population.
However, escape mutations carry an additional benefit of avoiding being killed by the immune system and therefore are expected to have a higher in
vivo fitness, which allows for persistence in spite of a lower replicative capacity. For this reason, even if the DFE of escape and non-escape mutations
are identical, the escape mutations derived from the patient population (blue) may appear to have on average a lower replicative capacity than the
non-escape mutations derived from the patient population (orange).
doi:10.1371/journal.pcbi.1002525.g002
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0.5%, see Materials & Methods) HLA-A molecules (absolute criterion: n~1229, relative criterion: n~854). We observed a significant correlation for
both epitope definitions (absolute criterion: r~{0:117, pv5|10{5; relative criterion: r~{0:128, pv5|10{4). For the sake of illustration, the blue
line shows the best fit of a linear regression and the 95% confidence interval.
doi:10.1371/journal.pcbi.1002525.g003
Figure 4. Cost of escape from the protective and the non-protective HLA alleles. (Top row) Effect of mutations on binding affinity to 10
most protective HLA molecules according to two alternative epitope definitions (absolute criterion: n~1223, relative criterion: n~721).
Protectiveness of alleles was characterized based on the relative hazard for AIDS progression (see Materials & Methods). A significant correlation
between the fitness of single mutants and the impairment of binding to the most protective HLA molecules was observed (absolute criterion:
r~{0:115, pv10{4; relative criterion: r~{0:0733, pv0:05). (Bottom row) Effect of mutations on binding affinity to 10 most non-protective HLA
molecules according to two alternative epitope definitions (absolute criterion: n~1069, relative criterion: n~631). In this case, no significant
correlation between the fitness of single mutants and the impairment of binding to the most non-protective HLA molecules was found (absolute
criterion: pw0:1; relative criterion: pw0:5). For the sake of illustration, the blue line shows the best fit of a linear regression and the 95% confidence
interval.
doi:10.1371/journal.pcbi.1002525.g004
Fitness Cost of Escape from HLA in HIV-1
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analysis was done on clinically derived sequences (cf. Fig. 2). This
intrinsic property of HLA binding is reflected as a significant
difference between fitness cost and change in binding to rare
HLA-A alleles, which are unlikely to exert any selective pressure at
the population level (see Fig. 3). Furthermore, we found that
mutations which help escape the protective HLA alleles (partic-
ularly HLA-A alleles) are associated with a higher fitness cost,
unlike mutations which help escape the non-protective HLA alleles
(see Fig. 4). This result also points to an intrinsic cost of escape as
the protective HLA alleles used in our analysis are not only on
average less frequent than the non-protective alleles, but also less
frequent than all other alleles used in this study (protective: 0.56%;
non-protective: 0.61%; all: 0.74%). We tested whether certain
biochemical properties of the peptides, such as hydrophobicity
[50,51], amino acid similarity [52] or GzC content [53] could
potentially underlie the observed intrinsic property of MHC
binding. However, even though such properties may partially
explain changes in binding to HLA molecules (e.g., change in
hydrophobicity according to [54,55]; see Fig. S1), none of them
significantly correlates with changes in fitness (pw0:1). Therefore,
what mechanism could explain that mutations which help to
escape HLA-A binding are associated with a replicative cost, and
whether intrinsic costs occur in other regions of the HIV-1
genome, remain open questions.
One of the most puzzling outcomes of this study is that no
significant fitness costs have been observed for escape mutations
from HLA-B molecules. This is surprising because HLA-B
molecules have been shown to have the strongest impact on the
outcome of HIV-1 infection: some HLA-B alleles have been
associated with long-term non-progression to AIDS [16,56,57],
and HLA-B restricted CTL responses have been shown to exert
the strongest selective pressure on the virus [11,58,59]. In line with
these observations, it has been previously shown that HLA-B
alleles target more conserved genetic regions of HIV-1 than HLA-
A alleles [60,61]. However, the fact that we do not observe a
significant cost of escape mutations from HLA-B can be
potentially attributed to several, mostly methodological factors.
First, a general feature of the currently available prediction
software is that binding predictions are more accurate for HLA-A
than for HLA-B, and this is also the case for netMHCpan used
here [37]. Second, the differences in fitness costs between HLA-A
and HLA-B could be due to an unknown property of the HIV-1
genomic region considered (PR and RT). Third, because the
mutations analyzed here are extracted from clinically derived
sequences, it is conceivable that the lack of a significant difference
between fitness of escape and non-escape mutations for HLA-B is
due to the differences between the distributions of HLA-A and
HLA-B alleles in the North American population. This topic,
however, warrants further investigation. For the reasons outlined
above, our results should not be used to suggest that escape from
HLA-A presentation is more costly than escape from HLA-B
presentation. Rather, our study emphasizes an important role of
HLA-A alleles (particularly the protective ones) in the evolution of
HIV-1, and RNA viruses in general, as suggested previously [62–
65].
One of the limitations of this study is that we have consistently
ignored all mutations outside the regions predicted to be restricted
by any HLA alleles used in the analysis (for the list see Table S1).
Interestingly, when we compared the fitness of mutations restricted
by HLA-A molecules to those not predicted to be restricted by any
of the HLA-A molecules used in this study, we found that
mutations in the restricted regions are on average less costly than
mutations in the non-restricted regions (absolute criterion:
pv0:05, relative criterion: pv0:001), and a similar effect was
found for HLA-B molecules (absolute criterion: pv0:0005,
relative criterion: pv0:05). The difference in fitness cost of the
restricted versus non-restricted regions may seem to contradict our
earlier conclusion that HLA-A molecules target regions which are
more costly for the virus to change. However, as the extent of
those regions strongly depends on the number of HLA molecules
considered in the analysis, as well as the binding threshold
considered, this result needs to be interpreted with caution. For
example, in the case of the relative criterion, we find that HLA-A
molecules span 60% and HLA-B span 67% of the considered
HIV-1 PR and RT, and for the absolute criterion these numbers
are even larger (85% and 98%, respectively). Even though we used
the largest subset of HLA molecules for which the employed
binding predictor works and for which frequency data in the US
population were obtained, these numbers constitute only a fraction
of the actual numbers of HLA alleles in the human population (98
out of known 486 HLA-A alleles and 184 out of known 817 HLA-
B alleles) [16]. It therefore seems likely that the non-restricted
regions here (i.e., those regions in which no peptide binds to any of
the HLA molecules included in the study) do bind to other HLA
molecules not included in this analysis, however this hypothesis
remains to be tested.
Another caveat of this study is that the viral fitness has been
assessed in an in vitro assay. This may be partially responsible for
the seemingly counter-intuitive fact that many single mutations
increase viral replicative capacity, as seen e.g. in Fig. 1.
Nevertheless, a recent study has shown that in vitro fitness measures
in PR and RT are indicative of in vivo HIV-1 virus load, suggesting
that our fitness measures are justified as a proxy for the virus
fitness in vivo [66].
It should also be noted that the correlations we observe
throughout this study are generally weak, suggesting that escape
from HLA-A presentation explains around 10% of the variance in
viral fitness. This may seem surprising as HLA molecules have
been shown as a potent factor in the evolution of HIV-1
[16,17,67,68]. However, there are several reasons to expect such
a result. First, HLAs are probably not the sole driver of the
evolution of the virus. Many of the mutations predicted to be non-
escape mutations could actually be escape mutations from other
elements of the antigen-processing and presentation pathway (e.g.,
TAP, proteasome, MHC class II), or from the recognition by the T
cell receptors [3]. Second, many epitopes are known to vary in
their immunogenicity, and some will be more likely to elicit CTL
responses than others [69]. Third, the signature of evolution in our
dataset will be strongly influenced by the population structure
from which the data was obtained, e.g., the distribution of HLA
allele frequencies. Fourth, the Pol gene analyzed here plays an
important role in the evolution of drug resistance, leading to a
potential interaction between immune- and treatment-mediated
selection (see below). Finally, the dataset used cannot provide any
insight into the distribution of the impairment of binding of
mutations with extremely high replicative fitness costs, because
such mutations will only be found at very low frequencies in the
patient population and may therefore be completely absent in the
dataset underlying our analysis. Overall, it is plausible that even if
CTL-mediated pressure is as strong as suggested previously
[26,70,71], many other factors (in addition to escape from HLA
class I) have influenced the evolution of HIV-1, resulting in a weak
correlation between replicative fitness and change in binding to
HLA molecules.
Can the implications of this analysis be extrapolated to the
entire HIV-1 genome? Previous studies showed that the Pol gene,
even though not as immunodominant as the Gag gene, can still
Fitness Cost of Escape from HLA in HIV-1
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immunity [11,72–74], and many optimal CTL epitopes have been
identified in the genetic region examined here [48]. Therefore, it is
conceivable that the effects observed here may be even stronger in
the most immunodominant HIV-1 proteins, like p24 Gag. Related
to this point is the fact that the gene analyzed here gives rise to many
known drug resistance mutations. Even though our results were
qualitatively identical when all such known mutations were excluded
[75], we observed an interesting interplay between in vitro fitness and
binding impairment for the subset of known drug resistance
mutations. In particular, we found a significant negative correlation
between fitness and binding impairment of those mutations to HLA-
A molecules for one of the criteria (absolute criterion: r~{0:27,
pv0:01; relative criterion: pw0:1), and a trend of a positive
correlation between fitness and binding impairment of those
mutations to HLA-B molecules (absolute criterion: r~0:172,
p~0:06; relative criterion: r~0:27, p~0:02). This could point to
an interesting interplay between the evolution of resistance and the
evolution of escape in HIV-1, as emphasized previously [76].
However, the exact character of this relation remains unclear.
Assessing the fitness cost of immune escape mutations presents a
crucial step towards a quantitative understanding of the dynamics
of infectious diseases and their interactions with the immune
system. To our knowledge, this study represents the first attempt to
quantify the cost of mutations on a large scale and to compare it
with the cost of mutations which do not affect the interaction with
the immune system. The fact that a relation between fitness cost of
mutations and their propensity to confer escape is not caused by a
population effect in the analyzed data suggests that MHC class I
molecules might have evolved to bind the genetic regions of RNA
viruses which are costly to change.
Supporting Information
Figure S1 Hydrophobicity vs. impairment of binding to HLA
alleles. Change in hydrophobicity (hydrophobicity of the mutant
amino acid minus hydrophobicity of the wild-type amino acid) was
correlated with the maximal impairment of binding to both HLA-
A and HLA-B alleles (see main text). A significant negative
correlation was found for all three measures of hydrophobicity and
for both binding criteria used (absolute criterion: r~{0:105,
pv10{4 [measure 1], r~{0:110, pv5|10{5 [measure 2],
r~{0:087, pv10{3 [measure 3]; relative criterion: r~{0:162,
pv10{8 [measure 1], r~{0:168, pv5|10{9 [measure 2],
r~{0:163, pv10{8 [measure 3]). The new consensus hydro-
phobicity scale was used as measure 1 (Tossi et al., 2002), the
pH 7.4 hydrophobicity scale was used as measure 2, and the
pH 2.1 hydrophobicity scale was used as measure 3 (Meek, 1980).
Even though the results shown here are obtained for both HLA-A
and HLA-B, the results for only HLA-A and only HLA-B were
qualitatively identical. For the sake of visibility, the blue line shows
the best fit of a linear regression with 95% confidence interval.
(TIF)
Table S1 The table lists all HLA alleles (A and B) used in the
analysis. The first row lists the HLA alleles in the four-digit
precision. The second row gives their expected frequency in the
US population (see also Materials & Methods).
(XLS)
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